A useful way to understand Dasatinib is to start with the biology it targets. Inhibits BCR-ABL and Src-family kinases, including resistant BCR-ABL variants. The target is a disease-defining tyrosine-kinase pathway in Philadelphia chromosome-positive leukemia, making molecular disease status central to its use. The database classifies it as Targeted Therapy; BCR-ABL Tyrosine Kinase Inhibitor and associates it with CML; ALL. Its principal oncology indications are Philadelphia chromosome-positive CML; Ph-positive ALL. Depending on the disease, the agent may appear as a single-agent treatment, a component of combination therapy, or part of a defined treatment sequence. The documented regimen examples are Dasatinib monotherapy; chemotherapy + dasatinib in Ph-positive ALL. Molecular and disease-specific eligibility can therefore be more important than tumor location alone when the treatment is considered. This distinction matters because treatment selection is not determined simply by the presence of a cancer diagnosis; the tumor subtype, disease stage, previous therapy, and molecular or receptor characteristics can narrow the appropriate setting. Its BCR-ABL/Src-family profile distinguishes it from other BCR-ABL inhibitors in the database and supports its listed use in Philadelphia chromosome-positive CML and ALL. The pharmacology helps explain its individual position among related medicines. Current labeling and the applicable oncology guideline should be consulted when the database is used for clinical reference.